MAPT and amyotrophic lateral sclerosis: As described before, ASOs downregulating C9Orf72 or MAPT (both predominantly causing a GoF effect when mutated) are currently being tested in C9-ALS and sporadic AD patients and may be tested in C9-FTD cohorts next (see above).